Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a blood coagulation factor presented as a sterile injectable solution for intravenous use. It replaces deficient factor VIII in patients with hemophilia A and related bleeding disorders. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanate is a factor VIII concentrate used in the management of bleeding disorders that involve the intrinsic coagulation pathway. - Hemophilia A (severe): provides replacement of deficient factor VIII to prevent or control spontaneous and traumatic bleeding. - Hemophilia A (moderate to mild): raises factor levels to reduce bleeding frequency and severity. - Acquired hemophilia A: supplies exogenous factor VIII to counteract auto‑antibody mediated deficiency. - Peri‑operative management: ensures adequate hemostasis during surgical procedures in patients with factor VIII deficiency.

Octanate may be associated with adverse reactions following infusion.

Common Side Effects: - Infusion‑related reactions: fever, chills, headache, nausea, arthralgia, fatigue. - Local site discomfort at the injection site. - Transient elevations in liver enzymes.

Serious or Rare Side Effects: - Development of neutralizing inhibitors (antibodies) against factor VIII. - Anaphylaxis or severe hypersensitivity reactions. - Thrombotic events, including deep vein thrombosis. - Transmission of viral pathogens (theoretical risk).

Octanate requires careful monitoring to ensure safety and efficacy. - Allergic reactions: observe patients for signs of hypersensitivity during and after infusion. - Inhibitor development: test for neutralizing antibodies regularly, especially in previously untreated patients. - Bleeding risk: adjust dosing based on clinical response and factor VIII activity levels. - Surgical procedures: confirm adequate factor levels before any invasive intervention. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other hemostatic agents, affecting coagulation balance.

Major Interactions (Avoid): - Activated prothrombin complex concentrates (aPCC): increased risk of thrombosis when combined with factor VIII. - High‑dose antifibrinolytics (e.g., tranexamic acid) in patients with a history of thromboembolic disease.

Moderate Interactions (Monitor Closely): - Other factor concentrates (e.g., factor IX): monitor for additive clotting effects. - Immunosuppressive therapies: may influence inhibitor development. - Vaccines administered concurrently: observe for enhanced immune response.